報價延遲最少15分鐘:2025/06/02 07:32 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
12 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.79/-1.29
|
|
企業價值
749.67M
|
| 資產負債 |
|
每股賬面淨值
5.00
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 07:32 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |